DrugPatentWatch Database Preview

QSYMIA Drug Profile

When do Qsymia patents expire, and when can generic versions of Qsymia launch?

Qsymia is a drug marketed by Vivus and is included in one NDA. There are ten patents protecting this drug and one Paragraph IV challenge.

This drug has sixty patent family members in seventeen countries.

The generic ingredient in QSYMIA is phentermine hydrochloride; topiramate. There are seventeen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the phentermine hydrochloride; topiramate profile page.

Summary for QSYMIA

International Patents:	60
US Patents:	10
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Bulk Api Vendors:	1
Clinical Trials:	8
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for QSYMIA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for QSYMIA
DailyMed Link:	QSYMIA at DailyMed

Drug patent expirations by year for QSYMIA

Generic Entry Opportunity Date for QSYMIA

Generic Entry Date for QSYMIA^: ➤ Sign Up* Constraining patent/regulatory exclusivity: ➤ Sign Up NDA: 022580 Dosage: CAPSULE, EXTENDED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for QSYMIA

Drug Class	Sympathomimetic Amine Anorectic
Mechanism of Action	Cytochrome P450 3A4 Inducers Cytochrome P450 2C19 Inhibitors
Physiological Effect	Appetite Suppression Increased Sympathetic Activity Decreased Central Nervous System Disorganized Electrical Activity

US Patents and Regulatory Information for QSYMIA

+ Get email alerts for changes to this table

Glossary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vivus	QSYMIA	phentermine hydrochloride; topiramate	CAPSULE, EXTENDED RELEASE;ORAL	022580-004	Jul 17, 2012		RX	Yes	Yes	➤ Sign Up	➤ Sign Up	Y			➤ Sign Up
Vivus	QSYMIA	phentermine hydrochloride; topiramate	CAPSULE, EXTENDED RELEASE;ORAL	022580-003	Jul 17, 2012		RX	Yes	No	➤ Sign Up	➤ Sign Up				➤ Sign Up
Vivus	QSYMIA	phentermine hydrochloride; topiramate	CAPSULE, EXTENDED RELEASE;ORAL	022580-004	Jul 17, 2012		RX	Yes	Yes	➤ Sign Up	➤ Sign Up	Y			➤ Sign Up
Vivus	QSYMIA	phentermine hydrochloride; topiramate	CAPSULE, EXTENDED RELEASE;ORAL	022580-003	Jul 17, 2012		RX	Yes	No	➤ Sign Up	➤ Sign Up	Y			➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration

Expired US Patents for QSYMIA

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Vivus	QSYMIA	phentermine hydrochloride; topiramate	CAPSULE, EXTENDED RELEASE;ORAL	022580-002	Jul 17, 2012	➤ Sign Up	➤ Sign Up
Vivus	QSYMIA	phentermine hydrochloride; topiramate	CAPSULE, EXTENDED RELEASE;ORAL	022580-001	Jul 17, 2012	➤ Sign Up	➤ Sign Up
Vivus	QSYMIA	phentermine hydrochloride; topiramate	CAPSULE, EXTENDED RELEASE;ORAL	022580-003	Jul 17, 2012	➤ Sign Up	➤ Sign Up
Vivus	QSYMIA	phentermine hydrochloride; topiramate	CAPSULE, EXTENDED RELEASE;ORAL	022580-004	Jul 17, 2012	➤ Sign Up	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration

Paragraph IV (Patent) Challenges for QSYMIA

Drugname	Dosage	Strength	RLD	Date
➤ Subscribe	Extended-release Capsules	3.75 mg/23 mg, 7.5 mg/46 mg, 11.25 mg/69 mg, 15 mg/92 mg	➤ Subscribe	➤ Sign Up

International Patents for QSYMIA

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Country	Document Number	Estimated Expiration
Hong Kong	1213489	➤ Sign Up
World Intellectual Property Organization (WIPO)	0076493	➤ Sign Up
Japan	5752595	➤ Sign Up
Spain	2291215	➤ Sign Up
Country	Document Number	Estimated Expiration

Summary for QSYMIA

Generic Entry Opportunity Date for QSYMIA

Pharmacology for QSYMIA

Paragraph IV (Patent) Challenges for QSYMIA

For more information try a trial or see the plans and pricing